Lung Cancer

Telcyta non-small cell lung cancer trial initiated

Published in Cancer Weekly, April 6th, 2004

Telik, Inc., (TELK) announced the initiation of a multicenter phase I-IIa clinical trial in which Telcyta (TLK286) will be evaluated in combination with cisplatin in the front-line treatment of stage IIIb or IV non-small cell lung cancer (NSCLC).

The trial is expected to enroll approximately 50 NSCLC patients who have not previously received chemotherapy. Platinum is the current mainstay of front-line metastatic lung cancer treatment.

The trial is based upon the clinical results reported at the AACR-NCI-EORTC meeting in November 2003 in which Telcyta demonstrated the ability to contribute to platinum-based chemotherapy without unanticipated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry